• 1-240-425-7688
  • info@bla-regulatory.com
logo
  • Services
    • Biopharmaceutical Consulting
      • Gap Analysis
      • Health Authority Meetings
      • IND Filing & Maintenance
      • Leading PI Recruitment
      • U.S. Agent Representation
      • Clinical Trials Registration
      • Strategy Development
      • Medical Writing
      • BLA, NDA Filing & Maintenance
      • Global Regulatory Reach
      • eCTD Publishing & Submission
      • Expedited Regulatory Programs
    • Medical Device Consulting
      • Medical Device Applications
      • Medical Device Reimbursement Services
    • Business Development Consulting
  • Consultants
  • About Us
    • About Us
    • FAQ
    • Career
  • Insights
    • Regulatory Intelligence
      • Weekly PharmaFocus
      • Monthly MedTech Orbit
      • Quarterly PharmaSphere
    • News
    • Events
    • Webinars
  • Contact

Home
no image found
Digital CRISPR gene editing technology showing DNA strands and genome modification for advanced cell and gene therapy development.

Prior Knowledge Advantage for GE Products: From US IND to BLA

...
Yuka Osada No Comments
no image found
Scientist using pipette and microscope to analyze biologic samples for biosimilar analytical similarity testing

Can Your Biosimilar Skip Phase 3 Trials? US FDA’s Biosimilar Rules Explained

...
Yuka Osada No Comments
no image found

Latest News: Proposed US-FDA Scrutiny on Cross-Border Clinical Data!

...
Yuka Osada No Comments
no image found

U.S. FDA Tightens Oversight of Cross-border Cell Exports!

...
Yuka Osada No Comments
no image found
US FDA CMC Strategy: CGT Comparability and BLA Readiness

US FDA CMC Strategy: CGT Comparability and BLA Readiness

...
Yuka Osada No Comments
no image found

PreCheck Program: FDA’s Roadmap for US Drug Manufacturing

...
Yuka Osada No Comments
no image found
Close-up of a human eye reflecting a colorful horizon, symbolizing the future of ophthalmic therapies and the evolving $79.4B eye-care landscape

Eye on the Horizon: The $79B Evolution of Ophthalmic Therapies

...
Yuka Osada No Comments
no image found
Infographic showing three root causes behind AAV gene therapy failures on the ‘CMC Cliff’: facility readiness issues, analytical uncertainty, and commercial viability challenges, each illustrated with examples and icons.

Navigating the 2026 “CMC Cliff” for AAV Gene Therapy

...
Yuka Osada No Comments
no image found
symbolizing drug shortage management and regulatory oversight

U.S. vs. Foreign Sponsors: Who Really Manages Drug Shortages?

...
Yuka Osada No Comments
no image found

Registration & Listing of Cosmetic Facilities and Products in the US

...
Yuka Osada No Comments
1 2 Next Page »

Join Our Newsletter
  Thank you for Signing Up
Please correct the marked field(s) below.
1,true,6,Contact Email,21,false,1,First Name,21,false,1,Last Name,2

 

610 Professional Dr. Suite 225
Gaithersburg, MD 20879

1-240-425-7668
info@bla-regulatory.com

© 2026 BLA Regulatory. All Rights Reserved.

Privacy Policy | Terms & Conditions

Website designed and maintained by USABAL Solutions